The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646983 | PMC |
| http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2100974 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tracking SARS-CoV-2 variants in wastewater in San Pedro de la Paz, Chile.
J Water Health
December 2024
Centro de Vigilancia de Aguas Residuales, Centinela Biobío, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción, Chile; Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción, Chile E-mail:
Studies have shown the presence of SARS-CoV-2 in the stool of both symptomatic and asymptomatic COVID-19 patients, enabling wastewater-based surveillance (WBS) to complement clinical monitoring. The emergence of variants can enhance viral transmissibility, highlighting the need for ongoing surveillance to detect and control infectious diseases. This study aimed to detect SARS-CoV-2 variants in wastewater from a treatment plant in San Pedro de la Paz, Chile, between January and November 2021.
View Article and Find Full Text PDFSecond-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate.
Vaccines (Basel)
October 2024
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Article Synopsis
- The COVID-19 pandemic illustrates how emerging viruses can disrupt global systems, exacerbated by factors like dense populations and environmental changes.
- Vaccines are critical in fighting outbreaks, and researchers have created a vaccine platform that can showcase multiple viral antigens simultaneously.
- This advanced platform uses engineered proteins to enhance vaccine effectiveness in mice, demonstrating the potential for quick development of vaccines for various infectious diseases.
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
J Virol
December 2024
Institute of Virology, Hannover Medical School, Hannover, Germany.
The effectiveness of SARS-CoV-2 therapeutic antibodies targeting the spike (S) receptor-binding domain (RBD) has been hampered by the emergence of variants of concern (VOCs), which have acquired mutations to escape neutralizing antibodies (nAbs). These mutations are not evenly distributed on the RBD surface but cluster on several distinct surfaces, suggesting an influence of the targeted epitope on the capacity to neutralize a broad range of VOCs. Here, we identified a potent nAb from convalescent patients targeting the receptor-binding domain of a broad range of SARS-CoV-2 VOCs.
View Article and Find Full Text PDFIFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes.
Int J Mol Sci
September 2024
Department of Immunology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland.
Interferons (IFNs) produced by airway epithelial cells are crucial in defending against pathogens. Fluctuations in IFN-λ levels may influence coronavirus disease 19 (COVID-19) severity. However, conflicting data have been reported regarding serum IFN-λ concentrations in COVID-19 patients.
View Article and Find Full Text PDFActive diagnostic ingredients (ADIs) for PCR: A mini-bioreactor producing dNTPs with silica immobilized R5-kinases.
Biotechnol Bioeng
December 2024
Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Low availability of routine nucleic acid amplification testing (NAAT) during infection outbreaks, especially in less resourced environments, was highlighted by the Covid pandemic. One of the barriers lies with the supply chain and cost of the active diagnostic ingredients (ADIs) that are the reagents for NAATs. This work explores a novel synthesis method to produce a key NAAT reagent, namely the 2'-deoxynucleoside 5'-triphosphate (dNTPs), via a reusable enzyme bioreactor, that can be integrated into a NAAT workflow.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!